ABSTRACT:
Sourabh D Jain*, Arun Kumar Gupta
Assistant Professor, Chameli Devi Institute of Pharmacy, Indore (M.P.) India.
*Corresponding Author E-mail: sourabhjain072@gmail.com
Tuberculosis is a serious global health problem, as one-third of the world’s population is estimated to be infected with Mycobacterium tuberculosis, and eight million new active cases occurred annually. Today, medicine is applied more technically and mechanically and on the other hand, effort is necessary not only for controlling the disease but also for increasing the quality of the life of patients. Quinolone comprise a relatively large, growing and most interesting group of antibacterial drugs which have made a major impact on the field of antimicrobial chemotherapy, particularly in the past few years. This is due to their potentiality offer many of the attributes of an ideal antibiotic, combining high potency, a broad spectrum of activity, good bioavailability, oral and intravenous formulations, high serum levels, a large volume of distribution indicating concentration in tissues and a potentially low incidence of side-effects. More researches have attempted to make these potential attributes continuously in the field of bacterial infections. After reviewing the current position on bacterial as well as tubercle bacillus, attempt was done, based on the above mentioned facts and explore some new derivatives of fluoroquinolone by synthesizing and evaluating the targeted bacterial organisms. So, it is desired the efficacy of new fluoroquinolone derivatives for the treatment of tuberculosis.
Cite this article:
Sourabh D Jain, Arun Kumar Gupta. Chemistry of Fluoroquinones in The Management of Tuberculosis (TB): An Overview. Asian J. Pharm. Res. 2021; 11(1):55-59. doi: 10.5958/2231-5691.2021.00011.3
Cite(Electronic):
Sourabh D Jain, Arun Kumar Gupta. Chemistry of Fluoroquinones in The Management of Tuberculosis (TB): An Overview. Asian J. Pharm. Res. 2021; 11(1):55-59. doi: 10.5958/2231-5691.2021.00011.3 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2021-11-1-11
REFERENCES:
1. Kumar V, Abbas AK, Fausto N, Mitchell RN, Robbins Basic Pathology 8th ed, Saunders Elsevier, Philadelphia, 2007; 516-522
2. Sravani K, Tuberculosis- A review of clinical features, differential diagnosis and treatments available, International Journal of Pharmacy and Technology, 2010; 2 (2): 206-207
3. Unalan D, Soyuer F, Ceyahn O, Basturk M, Ozturk A, Is the quality of life different in patient with active and inactive Tuberculosis?, Indian Journal of Tuberculosis, 2008; 55(3): 127-137
4. Narain JP, Pontali E, Tripathy S, Epidemiology and control strategies, Indian Journal of Tuberculosis, 2002; 49: 3-9
5. Kant S, Maurya A, Kushwaha AS, Nag VL, Multi-drug resistant tuberculosis: An iatrogenic problem, BioScience Trends, 2010; 4(2): 48-55
6. Swaminathan S, Clinical presentation and treatment of HIV-TB, Indian Journal of Tuberculosis, 2002; 49: 11-16
7. Walia K, Current issues in HIV / TB co-infection, Indian Journal of Tuberculosis, 2002; 49: 21-26
8. Zumla A, Raviglione M, Hafner R, Fordham VR, Current concepts: tuberculosis, New England Journal of Medicine, 2013; 368(8): 745–755
9. Margaret TH, Donald K, Principles of use of antibacterial agents, Infectious Disease Clinics of North America, 2004; 18: 435-436
10. Tekur U, Pharmacology antimicrobial agents: antibacterial drugs, 2007; 2-3
11. Kadam SS, Mahadik K R, Bothara K G, Principles of medicinal chemistry 20th ed. Pune: Nirali Prakashan; 2011; 10.4-10.5
12. Sharma H L, Sharma K K, Principles of pharmacology, 2nd ed, 2011;754-755
13. Lemke T L, Williams D A, Roche N F, Zito S W, Foye’s Principles of medicinal chemistry, 7th ed. 2013, 1179-1181
14. Brunton L, Chabner B, Knollman B, Goodman & Gilman’s The pharmacology basis of therapeutics, 12th ed, 2011; 1564-1565
15. Tripathi K D, Essentials of medical pharmacology 6th ed, 2008; 667-670
16. Emami S, Shafiee A, Foroumadi A, Quinolones: Recent structural and clinical developments. Iranian Journal of Pharmaceutical Research 2005; 3:123-136
17. Maureen K B, The newer fluoroquinolone, Medicinal Clinics of North America, 2001; 793-794
18. Sharma PC, Chaudhary M, Pahwa R, Sharma A, Dhamija M, Impact of stereochemical features on biological potential of fluoroquinolones, International Journal of Pharmaceutical Innovations, 2011; 1(1): 1-2
19. Negar M, Zahra A, Alipour E, Emami S, Synthesis and antibacterial activity of novel levofloxacin derivatives containing a substituted thienylethyl moiety, Journal of Pharmaceutical Sciences, 2012; 20: 2-6
20. Chen YL, Fang KC, Sheu JY, Tzeng CC, Synthesis and antibacterial evaluation of certain quinolone derivatives, Journal of Medicinal Chemistry, 2001; 44: 2374-2377
21. Cowper RM, Davidson LH, Organic synthesis, 2 nd ed, 1939, 19-24
22. Furniss BS, Hannaford AJ, Tatchell AR, Vogel’s Textbook of practical organic Chemistry 5th ed. 2011; 1050-1052
23. Saikia L, Baruah JM, Thakur AJ, A rapid, convenient, solventless green approach for the synthesis of oximes using grindstone chemistry, Organic and Medicinal Chemistry Letters, 2011; 41: 1-2
24. Bhopale GM, Importance of Fluoroquinolones in Human Healthcare: A Comprehensive Review, International Journal of Pharmaceutical Science and Research, 2014; 5(12): 5097-03
25. Emami S, Shafiee A, Foroumadi A, Quinolones: recent structural and clinical Developments, Iranian Journal of Pharmaceutical Research, 2005; 3: 123-125
26. Renau TE, Gage JW, Dever JA, Structure activity relationship of quinolone agents against mycobacterial, Antimicrobial agents and chemotherapy, 1996; 40(10): 2363-2364
27. Tillotson GS, Quinolone: Structure activity relationship and future prediction, Journal of Medicinal Microbiology, 1996; 44(5): 320-324
28. Daniel TW, Fernandez PB, Strucutr activity relationship of fluoroquinolone, Antimicrobial agents and Chemotherapy, 1989; 33():131-135
29. Rattan A, Mechanisms of resistance to fluoroqu2inolones, The National Medicinal Journal of India, 1999; 12(4): 162-163
30. Soni K, Fluoroquinolones: Chemistry & Action – A Review, Indo Global Journal of Pharmaceutical Sciences, 2012; 2(1): 43-53.